series-c-plus
Stage
2013
Founded
4
Investors
About
Editas Medicine develops CRISPR-Cas9-based gene editing therapies to treat genetic diseases, including programs targeting Usher syndrome and Duchenne muscular dystrophy.
Explore Editas Medicine's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.